On Probi´s Annual General Meeting on 7 May 2024, the following was resolved:
The Annual General Meeting approved the Annual Report and the Board's proposal on a dividend for the financial year 2023 corresponding to SEK 1.30 per share. The record date was set to 10 May 2024.
The Annual General Meeting resolved to approve the Board's remuneration report.
The Annual General Meeting discharged the Board members and the Chief Executive Officer from liability for the financial year 2023.
The Annual General Meeting resolved that the Board shall consist of five members without any deputies. The Annual General Meeting re-elected the Board members Jean-Yves Parisot, Jörn Andreas, Charlotte Hansson and Malin Ruijsenaars and resolved on new election of Stephanie Blum Sperisen as Board member. Jean-Yves Parisot was re-elected as Chairman of the Board.
The Annual General Meeting resolved that Board fees shall be paid in the amount of SEK 540,000 (SEK 540,000) to the Chairman and SEK 270,000 (SEK 270,000) to each of the other members. In addition, fee for committee work was determined to SEK 120,000 (SEK 120,000) to the Chairman of the Audit Committee and SEK 50,000 (SEK 50,000) to the other members, and SEK 30,000 (SEK 30,000) to Chairman of the Remuneration Committee and SEK 20,000 (SEK 20,000) to the other members.
The Annual General Meeting re-elected the registered public accounting firm Ernst & Young AB, which had informed that Peter Gunnarsson should be the auditor in charge, and resolved on fees to the auditor according to approved account.
The Annual General Meeting resolved, in accordance with the Board's proposal, on revised guidelines for remuneration to senior executives.
The Annual General Meeting resolved, in accordance with the Board's proposal, to autorize the Board to, for the period until the next Annual General Meeting and on one or several occasions, resolve on the issue of not more than 1,165,000 shares.
Presentation from the CEO is available on https://www.probi.com/investor-relations/presentations/
Probi® is a global Group that focuses exclusively on research, manufacturing and delivery of probiotics in dietary supplements and food. The company has expertise in managing live bacteria from research through all stages of the manufacturing process and is dedicated to making the health-promoting benefits of probiotics available to people around the world. Since the company was founded in 1991 at Lund University in Sweden, Probi has expanded its operations to more than 40 markets and holds more than 400 patents worldwide. Probi had sales of SEK 628 m in 2023. Probi's shares are listed on Nasdaq Stockholm, Mid-cap, and there were around 3,400 shareholders on December 31, 2023.
Attachments:
05075395.pdf
This news release was distributed by Company News System, www.nasdaqomxnordic.com/news/marketnotices
To subscribe on regulatory news from this company, go to the subscription page
Attachments
Original Link
Permalink
Disclaimer
Probi AB published this content on
07 May 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
07 May 2024 14:27:05 UTC.
Probi AB is a Sweden-based company engaged in the probiotics research and development. The Companyâs activities are divided into two business areas: Functional Foods, which focuses on the probiotics application in food in partnership with food companies; and Consumer Healthcares, which develops, commercializes and sells Probi probiotics in collaboration with a range of entities, such as pharmaceutical companies and firms related to the production of probiotics and self-care goods. Its brands portfolio comprises two trademarks: Probi Digestis and Probi Defendum. The Company's partners include Danone, Skanemejerier, NextFoods, Sanum Polska, Heinz, Kraft Foods, and Institut Rosell, among others. The Company is a parent of Probi Food AB and Probi Feed AB.